<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                             November 6, 2024

Robert Labbe
Chief Executive Officer
Pelican Acquisition Corp
1185 Avenue of the Americas, Suite 301
New York, NY 10036

       Re: Pelican Acquisition Corp
           Draft Registration Statement on Form S-1
           Submitted on October 10, 2024
           CIK No. 0002037431
Dear Robert Labbe:

       We have reviewed your draft registration statement and have the
following comments.

       Please respond to this letter by providing the requested information and
either
submitting an amended draft registration statement or publicly filing your
registration
statement on EDGAR. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

      After reviewing the information you provide in response to this letter
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Draft Registration Statement on Form S-1 Submitted on October 10, 2024
Cover Page

1.     We note your disclosure regarding founder shares issued to the sponsor
and the
       private units to be issued to the sponsor. Please revise to (i) disclose
the amount the
       sponsor paid for the founder shares and the private units, and (ii)
include cross-
       references to all disclosures related to compensation and the issuance
of securities to
       sponsors, sponsor affiliates and promoters in the prospectus. See Item
1602(a)(3) of
       Regulation S-K.
2.     Please revise the cover page to state the time frame for the special
purpose acquisition
       company to consummate a deSPAC transaction and whether this time frame
may be
       extended. See Item 1602(a)(1) of Regulation S-K.
3.     Where you discuss conflicts of interest, please include additional
cross-references to
 November 6, 2024
Page 2

       the locations of related disclosures in the prospectus, such as in the
summary
       disclosure provided in response to Item 1602(b)(7).
4.     We note potential conflicts of interest disclosure on the cover page.
Please clearly
       state that there may be actual or potential material conflicts of
interest between the
       sponsor, its affiliates, or promoters; and purchasers in the offering.
Please also revise
       your cross-references to include cross-references to all related
disclosures in the
       prospectus. See Item 1602(a)(5) of Regulation S-K.
5.     Please revise to address the working capital loans and the repayment of
the non-
       interest bearing loans which may be made by your initial shareholders or
affiliates and
       that up to $1,500,000 of the loans may be converted into private units
at a price of
       $10.00 per unit.
6.     We note you indicate that because of the nominal price paid for the
founder shares,
       the public shareholders will incur substantial dilution. Please address
whether
       compensation may result in a material dilution of the purchasers
equity interests. See
       Item 1602(a)(3) of Regulation S-K.
7.     Please revise to indicate the price EarlyBirdCapital, Inc. paid for the
500,000 shares
       that are the EBC founder shares.
8.     Please clarify that there are permitted withdrawals from the interest
earned on Trust
       account of $250,000 annually to fund working capital requirements.
9.     Please clarify how long the $15,000 per month for office space and
administrative
       services will be paid.
Prospectus Summary, page 1

10.    Please expand your discussion of the manner in which you will identify
and evaluate
       potential business combination candidates to include disclosure of how
significant
       competition among other SPACs pursuing business combination transactions
       may impact your ability to identify and evaluate a target company.
11.    We note your disclosure that you may need to obtain additional financing
for working
       capital needs and transaction costs in connection with the search and
completion of
       the initial business combination, to complete an initial business
combination, or
       because you become obligated to redeem a significant number of your
public shares.
       Please describe how additional financings may impact unaffiliated
security holders.
       See Item 1602(b)(5) of Regulation S-K.
Our Company, page 2

12.    Please expand your disclosure to clearly identify any special purpose
acquisition
       company business combinations in which the sponsor or your management
team has
       participated. For each SPAC, include disclosure regarding completed
business
       combinations, liquidations, pending de-SPAC transactions and whether
such SPAC is
       still searching for a target.
Initial Business Combination, page 6

13.    Please disclose your plans if you do not consummate a de-SPAC
transaction
       within 24 months if you have entered into a definitive agreement for an
initial
 November 6, 2024
Page 3

       business combination, including whether you expect to extend the time
period,
       whether there are any limitations on the number of extensions, including
the number
       of times, and the consequences to the SPAC sponsor of not completing an
extension
       of this time period. Please also disclose whether security holders will
have voting or
       redemption rights with respect to any extensions. See Item 1602(b)(4) of
Regulation
       S-K.
Our Sponsor, page 9

14.    We note disclosure beginning on page 25 regarding limited payments that
may be
       made to insiders, including your sponsor, officers, directors and their
affiliates. Please
       revise your compensation table on page 9 to reference the potential
payments that may
       be made to your sponsor, its affiliates or promoters of any fees for
their services
       rendered prior to or in connection with the completion of the initial
business
       combination. Please also disclose the anti-dilution adjustment of the
founder shares in
       the table. Also describe the extent to which any compensation or
securities issuance to
       the sponsor, its affiliates or promoters may result in a material
dilution of the
       purchasers    equity interests. See Items 1602(b)(6) and 1603(a)(6) of
Regulation S-K.
15.    In the table of compensation and securities issued or to be issued,
please include the
       private placement equivalent units that may be issued to the sponsor
upon conversion
       of up to $1,500,000 of working capital loans at a price of $10.00 per
unit. Please also
       include this disclosure on the cover page, as required by Items
1602(a)(3) and
       1602(b)(6) of Regulation S-K.
16.    We note your tabular compensation table indicates 100,000 private units
to be
       purchased by your Sponsor at a price of $1,000,000. We note your
disclosure on the
       cover page and in the summary that the Sponsor will be purchasing
275,000 private
       units for $2,750,000. Please revise the tabular disclosure to include
the 275,000
       private units to be purchased by your Sponsor at a price of $10.00 per
unit or revise
       your disclosures as appropriate. See Items 1602(b)(6) and 1603(a)(6) of
Regulation S-
       K.
17.    We note that Daniel M. MCabe is the manager of your sponsor and has
voting and
       dispositive power over the shares owned by Pelican Sponsor LLC. Please
revise to
       identity of all persons who have direct and indirect material interests
in the SPAC
       sponsor and the nature and amount of those interests. See Item
1603(a)(7) of
       Regulation S-K.
18.    Please clarify how long the $15,000 per month for office space and
administrative
       services will be paid.
Liquidation if no business combination, page 22

19.    Please reconcile disclosure on page here and elsewhere stating that you
may use up to
       $50,000 of interest on the assets in the Trust Account to pay
liquidation and
       dissolution expenses with disclosure on page 24 stating that you will
pay the costs,
       anticipated to be no more than $100,000, of liquidating the Trust
Account from assets
       outside of the Trust Account.
 November 6, 2024
Page 4

Conflicts of Interest, page 24

20.    Please revise your disclosure in this section and in similar disclosure
beginning on
       page 101 to clearly state that there are actual or potential material
conflicts between
       the SPAC sponsor, its affiliates or promoters; and purchasers in the
offering. Briefly
       describe all such actual or potential material conflicts, including
those that may arise
       in determining whether to pursue a de-SPAC transaction. For example, you
should
       discuss potential material conflicts relating to the financial interests
of the sponsor, its
       affiliates and promoters in completing any de-SPAC transaction within
the allotted
       time, as well as the fact that the company may pursue a de-SPAC
transaction with a
       target that is affiliated with the sponsor, its affiliates, directors,
or promotors as noted
       on page 5. Please see Item 1602(b)(7) and Item 1603(b) of Regulation
S-K.
21.    Please provide the basis for your statements here and throughout the
prospectus that
       you do not believe any fiduciary duties or contractual obligations of
your directors or
       officers would materially undermine your ability to complete our
business
       combination.
Risk Factors, page 31

22.    We note the disclosure on page 10 that in order to facilitate your
initial business
       combination or for any other reason determined by your sponsor in its
sole discretion,
       your sponsor may surrender or forfeit, transfer or exchange your founder
shares,
       private placement warrants or any of your other securities, including
for no
       consideration, as well as subject any such securities to earn-outs or
other restrictions,
       or otherwise amend the terms of any such securities or enter into any
other
       arrangements with respect to any such securities. Please add risk factor
disclosure
       about risks that may arise from the sponsor having the ability to remove
itself as your
       sponsor before identifying a business combination, including through the
       unconditional ability to transfer the founder shares or otherwise.
If we are deemed to be an investment company ..., page 57

23.    Please revise this risk factor to clearly state that notwithstanding
your investment in
       U.S. government treasury securities or money market funds meeting
conditions under
       Rule 2a7, you may still be found to be operating as an unregistered
investment
       company. Please also include disclosure with respect to the consequences
to investors
       if you are required to wind down your operations as a result of this
status, such as the
       losses of the investment opportunity in a target company, any price
appreciation in the
       combined company, and any warrants, which would expire worthless.
The value of the founder shares following completion of our initial business
combination...,
page 61

24.    We note your cover page indicates that the Sponsor will purchase 275,000
private
       units at $10 per unit for a total of $2,750,000, assuming no exercise of
the
       underwriters    over-allotment option. We also note your disclosure that
   our Sponsor
       and its affiliates will have invested in us an aggregate of $10,025,000,
comprised of
       the $25,000 purchase price for the founder shares and the $10,000,000
purchase price
       for the private placement units.    Additionally, the valuation later in
the paragraph
 November 6, 2024
Page 5

       appears incorrect. Please revise or advise us as appropriate.
Use of Proceeds, page 70

25.    We note that footnotes (3) and (4) appear repetitive. Please revise.
Dilution, page 74

26.    We note that one of your calculations assumptions is that no ordinary
shares and
       convertible equity or debt securities are issued in connection with
additional financing
       in connection with an initial business combination. Please expand your
disclosure to
       highlight that you may need to do so as you intend to target an initial
business
       combination with a target company whose enterprise value is greater than
you could
       acquire with the net proceeds of the offering and the sale of private
placement shares,
       as stated on page 84 of your prospectus.
       Please contact Frank Knapp at 202-551-3805 or Wilson Lee at 202-551-3468
if you
have questions regarding comments on the financial statements and related
matters. Please
contact Pearlyne Paulemon at 202-551-8714 or David Link at 202-551-3356 with
any other
questions.



                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Real
Estate & Construction
cc:   Cassi Olson
</TEXT>
</DOCUMENT>
